611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Reports Second Quarter 2025 Financial Results and Provides Business Update
Material disclosure
Reports First Quarter 2025 Financial Results and Provides Business Update
Annual Report to Security Holders
Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
Changes in Board, Management or Compensation
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provides Business Update and 2025 Outlook
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership